AstraZeneca joins Boehringer Ingelheim in capping out-of-pocket inhaler costs at $35

Katherine Lewin

News Reporter

Just as insulin manufacturers were pressured into capping monthly out-of-pocket costs, inhaler manufacturers are feeling the same heat. AstraZeneca on Monday joined with Boehringer Ingelheim …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca joins Boehringer Ingelheim in capping out-of-pocket inhaler costs at $35

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

As­traZeneca joins Boehringer In­gel­heim in cap­ping out-of-pock­et in­haler costs at $35

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca joins Boehringer Ingelheim in capping out-of-pocket inhaler costs at $35